Examining Women’s Dental Disorders through Multi-Level Sex and Gender Analysis

The Food and Drug Administration (FDA) approves drugs for sale in the United States based on its determination that the clinical benefits of a drug outweigh its potential health risks.To make this decision, FDA reviews supporting data collected from several thousand patients during the drug's development.Once a drug is approved for marketing and used by potentially hundreds of thousands of patients, however, the type, rate, and severity of adverse events caused by the drug can be much different than those detected during the drug's development.In some cases, FDA or drug manufacturers have acted to remove from the market drugs that have been shown to have unacceptable health risks once they were in widespread use.You requested that we identify drug products withdrawn from the market in the United States since January 1, 1997, and that we note which of the withdrawn drugs posed greater health risks for women than for men.We collected this information from publicly available sources, primarily FDA documents and research articles from the medical literature.We also consulted drug safety experts.We looked only at prescription pharmaceuticals, not at vaccines or over-the-counter medicines.1 We conducted our work from December 2000 to January 2001 in accordance with generally accepted government auditing standards

Oral health · Sociology · Dentistry · Gender Studies · Medicine · Psychology · Sex and Gender in Healthcare · Sexual Assault and Victimization Studies · Gerontology